FDA Crackdown Hits Ozempic Copycats

Pharmacist assists customer at pharmacy counter — Photo: Zamrznuti tonovi / Shutterstock

Millions of Americans turned to cheaper, pharmacy-made versions of Ozempic and Wegovy, and now federal regulators say some of those drugs were never properly reviewed for safety at all.

Quick Take

The FDA issued a warning letter to Houston-based Empower Pharmacy over sterility and labeling problems in its compounded GLP-1 drugs.
Novo Nordisk sued Hims & Hers in February 2026 after the company sold a $49 compounded weight-loss pill, then dropped the suit weeks later.
The FDA has logged hospitalizations tied to dosing errors, some involving doses five to twenty times too strong.
Federal appeals judges confirmed the semaglutide shortage that justified mass compounding is officially over.

Why Compounding Pharmacies Boomed in the First Place

Demand for GLP-1 weight-loss drugs exploded faster than Novo Nordisk and Eli Lilly could make them. Starting in 2022, semaglutide and tirzepatide landed on the FDA’s official shortage list. Federal law allows pharmacies to compound copies of drugs in short supply, so thousands of compounding pharmacies and telehealth startups rushed in to fill the gap with cheaper, custom-mixed versions.

The Warning Letter That Exposed a Core Legal Problem

Empower Pharmacy became the industry’s biggest cautionary tale. On September 18, 2026, the FDA sent the company a warning letter after inspectors found its compounded tirzepatide and semaglutide products looked like near-copies of the brand-name drugs, not individualized treatments. Inspectors also flagged sterility failures and noted Empower mixed in extra ingredients like B vitamins, a move regulators said sidestepped the legal rules meant to limit mass production. That distinction matters more than it sounds. Federal compounding law, known as Section 503A, only protects pharmacies that make drugs for a specific named patient based on real medical need, not products churned out at industrial scale to undercut brand prices. Once a compounded drug becomes a near-match for an approved one, selling it in bulk starts to look less like personalized medicine and more like unapproved manufacturing.

Novo Nordisk’s Lawsuit and the Fight Over a $49 Pill

The clash went public in February 2026 when Hims & Hers began marketing a compounded semaglutide pill for $49, roughly $100 cheaper than Novo Nordisk’s own direct-to-consumer price. Novo Nordisk sued for patent infringement, calling it “mass illegal compounding”. The FDA backed that pressure the same week, announcing plans to restrict the active ingredients compounders use to mass-produce GLP-1 copies. Hims pulled the product almost immediately, and Novo Nordisk ended the lawsuit in March once the pill was gone.

Dosing Errors Are the Real Safety Stakes for Patients

Beyond the legal fights, the FDA says real people have been hurt. The agency received reports of hospitalizations tied to patients and even some health workers miscalculating semaglutide doses, with some overdoses reaching five to twenty times the intended amount. Compounded drugs skip the FDA’s standard safety and quality review, so concentration can vary from batch to batch and pharmacy to pharmacy, leaving patients with little way to verify what they’re actually injecting.

Excited to be quoted by CBS News on the FDA’s latest warning letter to compounding pharmacies producing GLP-1 weight-loss drugs. https://t.co/HBGIp8P7Yo #klf #kulkarnilawfirm #peptides #glp1 #pharmacy #compounding pic.twitter.com/qIbi7QOiRR

— Kulkarni Law Firm (@kulkarnilawfirm) October 1, 2026

The FDA didn’t stop at drugmakers. In 2026 it also sent warning letters to 30 telehealth companies, accusing them of marketing compounded GLP-1s with misleading claims, including calling them equivalent to FDA-approved brands. For consumers scrolling weight-loss ads online, that’s the detail worth remembering: a slick website and a doctor’s signature don’t guarantee the product meets the same bar as Ozempic or Zepbound off a pharmacy shelf.

Last summer, the Fifth Circuit Court of Appeals upheld the FDA’s finding that the national semaglutide shortage is officially over, stripping away the legal justification that let mass compounding flourish. Common sense suggests the current crackdown reflects that shift rather than any sudden discovery of danger. Patients weighing a compounded GLP-1 should ask their pharmacist hard questions about sourcing, sterility testing, and whether genuine medical necessity, not just a lower price, justifies skipping the FDA-approved version.